期刊
DIGESTIVE AND LIVER DISEASE
卷 47, 期 3, 页码 226-232出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.dld.2014.11.015
关键词
Insulin sensitivity; Metabolic syndrome; Nutrition
资金
- National Natural Science Foundation of China [30972469, 81273059]
- Science and Technology Key Project Foundation of Chongqing [CSTC, 2011AB5040]
- National Science-technology Support Plan Projects Foundation of China [2012BAI35B02]
Background: Non-alcoholic fatty liver disease is a major health problem worldwide. Resveratrol is a natural polyphenol found in edible plants that has a variety of biochemical and physiological effects. Aims: To evaluate the effect of resveratrol on insulin resistance, glucose and lipid metabolism in nonalcoholic fatty liver disease. Methods: Double-blind, randomized, placebo-controlled trial: 60 subjects with non-alcoholic fatty liver disease were given 2 placebo capsules (placebo group) or 2 150 mg resveratrol capsules (resveratrol group) twice daily for three months. Liver ultrasound imaging, anthropometric profile, serum liver enzymes, insulin, glucose, C-peptide, lipid profile, and inflammation-related cytokines were compared pre and post-treatment. Results: Compared with the placebo group, resveratrol significantly decreased aspartate aminotransferase, glucose and low-density lipoprotein cholesterol [-6.00 (-9.00, -3.00) IU/L, -0.64 +/- 0.31 mmol/L, and -0.41 +/- 0.35 mmol/L, respectively, P <= 0.001] alanine aminotransferase, total cholesterol [7.00 (-11.0, -2.50) IU/L and -0.67 +/- 0.50 mmol/L, respectively, P=0.002], and homeostasis model assessment insulin resistance index (-0.60 +/- 1.15, P=0.016). In the resveratrol group significant reductions of the levels of tumour necrosis factor-alpha, cytokeratin 18 fragment, and fibroblast growth factor 21 [0.53 +/- 1.30 pg/mL, 26.9 (70.3, 5.12) IU/L and 23.3 (43.0, 0.31) pg/mL, respectively, P < 0.05] and elevation of adiponectin level [1.22 (-0.37, 1.60) ng/mL, P=0.025] were observed. Conclusion: Resveratrol supplementation may benefit patients with non-alcoholic fatty liver disease. (C) 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据